Multivariate analysis and molecular interaction of curcumin with PPARγ in high fructose diet induced insulin resistance in rats

Unravelling the prophylactic anti-inflammatory potential of Koenigia tortuosa through modulation of cytokine levels and inflammatory markers in LPS-induced localized inflammation in Wistar rat models

Chronic inflammation, a pivotal factor in various chronic diseases, necessitates safe and effective treatments to alleviate disease severity and symptoms. Current interventional approaches, including synthetic steroids and non-steroidal anti-inflammatory drugs, pose safety concerns. Consequently, people seek plant-based alternatives as safer substitutes. Koenigia tortuosa, a medicinal plant with rich folklore claims, traditionally treats joint pain, swelling, dysentery and kidney related problems but lacks documentation. This study investigated anti-inflammatory properties of Koenigia tortuosa. Soxhlet extraction method was employed to obtain five different extracts of Koenigia tortuosa viz., hexane (95%), ethyl-acetate (99%), ethanol (99%), methanol (95%) and aqueous. Anti-inflammatory potential of different extracts was determined by both in vitro (including protein denaturation, nitric-oxide scavenging, proteinase inhibition, and erythrocyte membrane stabilization) and in vivo by performing histopathological studies and determining levels of various inflammatory markers like IL-1β, IL-6, IFN-γ and TNF-α using ELISA and, iNOS, PPAR-γ and COX-2 by Western blotting. GC-MS analysis was performed to reveal the bioactive compounds in extracts. At 600 μg/mL, two extracts, ethyl acetate and methanolic extract exhibited maximum inhibition of protein denaturation 75.07% ± 3.28% and 64.97% ± 1.73%, nitric oxide activity 88.06% ± 3.49% and 82.09% ± 3.61%, proteinase activity 82.06% ± 2.98% and 71.06% ± 3.58%, and erythrocyte-membrane haemolysis 84.94% ± 4.14% and 72.97% ± 4.68%, respectively (P < 0.001). In vivo studies using Wistar rats demonstrated no toxic effects of ethyl acetate and methanolic extract upon oral administration. These two extracts modulated cytokine levels and inflammatory markers, showing concentration dependent reductions in levels of IL-6, IL1-β, IFN-γ, TNF-α (P < 0.001), iNOS, COX-2 in LPS -induced inflammation in Wistar rats. At a dose of 100 mg/kgbwt, KTEA administration resulted in a substantial decrease in cytokine levels: IL1β from 68.99 ± 1.83 pg/mL to 31.68 ± 1.90 pg/mL (P < 0.001), IL6 from 80.40 ± 0.70 pg/mL to 39.47 ± 1.85 pg/mL (P < 0.01), TNFα from 71.34 ± 2.35 pg/mL to 29.37 ± 2.20 pg/mL (P < 0.001), and IFNγ from 120.27 ± 4.26 pg/mL to 68.07 ± 2.78 (P < 0.01) pg/mL. Similarly, a concentration dependent decrease in prostaglandins (273.68 pg/mL and 418.96 pg/mL by ethyl acetate and methanolic extract at 100 mg/kgbwt) and leukotrienes (239.37 pg/mL and 302.19 pg/mL by ethyl acetate and methanolic extract at 100 mg/kgBwt) were observed as compared with the LPS induced group (prostaglandins 1129.99 pg/mL and leukotrienes 558.67 pg/mL). We also observed that Koenigia tortuosa extracts improves the levels of lymphocytes and leukocytes. Notably, PPAR-γ expression exhibited a concentration dependent increase, suggesting potential anti-inflammatory effects through nuclear receptor modulation. Histopathological investigations demonstrated significant healing effects of extracts. Analysis using GC-MS unveiled the presence of bioactive compounds with potent anti-inflammatory properties. These findings suggest Koenigia tortuousa's anti-inflammatory mechanisms and potential therapeutic applications.

Lycopene Modulates Oxidative Stress and Inflammation in Hypercholesterolemic Rats

The complicated disorder of hypercholesterolemia has several underlying factors, including genetic and lifestyle factors. Low LDL cholesterol and elevated serum total cholesterol are its defining features. A carotenoid with antioxidant quality is lycopene. Examining lycopene activity in an animal model of hypercholesterolemia induced using food was the aim of this investigation. Triglycerides, LDL cholesterol, HDL cholesterol, and plasma total cholesterol were all measured. Biomarkers of renal and cardiac function were also examined. Apoptotic indicators, pro-inflammatory markers, and oxidative stress were also assessed. Additionally, the mRNA expression of paraoxonase 1 (PON-1), peroxisome proliferator-activated receptor gamma (PPAR-γ), and PPAR-γ coactivator 1 alpha (PGC-1α) in cardiac and renal tissues was examined. Rats showed elevated serum lipid levels, renal and cardiac dysfunction, significant oxidative stress, and pro-inflammatory and apoptotic markers at the end of the study. Treatment with lycopene significantly corrected and restored these changes. Additionally, lycopene markedly increased the mRNA expression of PGC-1α and PON-1, and decreased PPAR-γ expression. It was determined that lycopene has the capacity to modulate the PPAR-γ and PON-1 signaling pathway in order to preserve the cellular energy metabolism of the heart and kidney, which in turn reduces tissue inflammatory response and apoptosis. According to these findings, lycopene may be utilized as a medication to treat hypercholesterolemia. However, further studies should be conducted first to determine the appropriate dose and any adverse effects that may appear after lycopene usage in humans.

Antitoxic Effects of Curcumin against Obesity-Induced Multi-Organs' Biochemical and Histopathological Abnormalities in an Animal Model

Background

Obesity is a significant public health problem that is characterized by an increase in oxidative stress and enhanced inflammatory responses associated with immune cell invasion of adipose tissues. This study assessed several biochemical abnormalities, apoptosis, oxidative stress status, and associated histological changes in the liver, duodenum, and heart brought on by high-fat diet-induced obesity in rats. It also assessed the mechanistic benefits of curcumin in reversing these inflammatory, metabolic, and histological impairments.

Methods

Rats were assigned into three groups each including ten rats: the control group (CD), the high-fat diet group (HFD), and the high-fat diet + curcumin (HFDC) group. Serum glucose, insulin, and triglycerides (TAGs) were observed. In addition, apoptosis (indicated by hepatic DNA fragmentation) and oxidative stress status (indicated by hepatic MPO, GSH, and SOD) were assessed. Histopathological examinations included the GIT (liver and duodenum) and heart in addition to quantitative real-time polymerase chain reaction (qRT-PCR) assays of the adipose tissue genetic expressions for inflammatory signaling pathways (TLR4, IL-6, and TNF-α).

Results

The overall findings showed that the HFD group exhibited significantly higher levels of glucose, TAGs, and insulin than the control group (P < 0.01). The histological abnormalities of the studied organs in the HFD group were paralleled by these biochemical abnormalities, which were strongly associated with increased apoptosis, increased oxidative stress, and increased expression of the inflammatory signaling markers. There were significant improvements in the HFDC group in terms of biochemical, inflammatory, and histological investigations.

Conclusions

This study's findings concluded that obesity is significantly associated with biochemical and microscopic alterations in many organs. Curcumin exerted potent antitoxic, antioxidant, tissue-protective, and antiobesity effects. Curcumin is recommended to be added to various dietary regimens to prevent or delay the organs' dysfunction among obese people.

Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments

Peroxisome proliferator-activated receptors (PPARs) are members of the ligand-dependent nuclear receptor family. PPARs have attracted wide attention as pharmacologic mediators to manage multiple diseases and their underlying signaling targets. They mediate a broad range of specific biological activities and multiple organ toxicity, including cellular differentiation, metabolic syndrome, cancer, atherosclerosis, neurodegeneration, cardiovascular diseases, and inflammation related to their up/downstream signaling pathways. Consequently, several types of selective PPAR ligands, such as fibrates and thiazolidinediones (TZDs), have been approved as their pharmacological agonists. Despite these advances, the use of PPAR agonists is known to cause adverse effects in various systems. Conversely, some naturally occurring PPAR agonists, including polyunsaturated fatty acids and natural endogenous PPAR agonists curcumin and resveratrol, have been introduced as safe agonists as a result of their clinical evidence or preclinical experiments. This review focuses on research on plant-derived active ingredients (natural phytochemicals) as potential safe and promising PPAR agonists. Moreover, it provides a comprehensive review and critique of the role of phytochemicals in PPARs-related diseases and provides an understanding of phytochemical-mediated PPAR-dependent and -independent cascades. The findings of this research will help to define the functions of phytochemicals as potent PPAR pharmacological agonists in underlying disease mechanisms and their related complications.

Antidiabetic Properties of Curcumin: Insights on New Mechanisms

Plant extracts have been used to treat a wide range of human diseases. Curcumin, a bioactive polyphenol derived from Curcuma longa L., exhibits therapeutic effects against diabetes while only negligible adverse effects have been observed. Antioxidant and anti-inflammatory properties of curcumin are the main and well-recognized pharmacological effects that might explain its antidiabetic effects. Additionally, curcumin may regulate novel signaling molecules and enzymes involved in the pathophysiology of diabetes, including glucagon-like peptide-1, dipeptidyl peptidase-4, glucose transporters, alpha-glycosidase, alpha-amylase, and peroxisome proliferator-activated receptor gamma (PPARγ). Recent findings from in vitro and in vivo studies on novel signaling pathways involved in the potential beneficial effects of curcumin for the treatment of diabetes are discussed in this review.

Molecular docking analysis and anti-hyperglycaemic activity of Synacinn™ in streptozotocin-induced rats

Synacinn™ is a standardized polyherbal supplement formulated from Cinnamomum zeylanicum Blume, Curcuma zanthorrhiza Roxb., Syzygium polyanthum (Wight) Walp., Orthosiphon stamineus Benth. and Andrographis paniculata (Burm.f.) Nees. It is designed for the synergistic treatment of diabetes mellitus and its complications. Although the beneficial effects are yet to be verified scientifically, it is traditionally used to improve general health in patients with diabetes. This study aimed to evaluate the anti-hyperglycemic effects of Synacinn™ in a streptozotocin-induced type 1 diabetes rat model. Initially, Synacinn™ was used for in vivo acute oral toxicity tests and 14 day repeated dose toxicity tests to determine the toxicity levels. An efficacy study of Synacinn™ was carried out via the oral administration of 10, 50, 100, 250, and 250 (b.i.d.) mg kg-1 doses to streptozotocin-induced diabetic rats. After 28 days, blood serum was collected to measure the fasting blood glucose, triglyceride, cholesterol, alanine aminotransferase, alkaline phosphatase, creatinine, and uric acid levels. The liver, kidney, and pancreas structures were histopathologically analyzed. In silico binding interaction studies of five phytochemicals in Synacinn™ identified via HPLC with glucokinase were performed using molecular docking analysis. The results showed that although no mortality was observed during the acute oral toxicity tests, notable damage to the liver and kidney occurred during the 14 day repeated dose testing at Synacinn™ levels of 600 mg kg-1 and 2000 mg kg-1. Treatment with 250 mg kg-1 (b.i.d.) Synacinn™ of the streptozotocin-induced type 1 diabetic rats significantly (p < 0.05) improved the fasting blood glucose (59%), triglyceride (58%), cholesterol (47%), alanine aminotransferase (60%), alkaline phosphatase (90%), and creatinine (32%) levels. Synacinn™ also improved the relative weights of liver (35%), kidney (36%), and pancreatic (36%) tissue. Histological analysis showed improvements in the conditions of the central vein of the liver, the kidney Bowman's capsule and glomerulus, and the pancreatic islets of Langerhans. HPLC analysis of a standardized extract identified five active phytochemicals: andrographolide (17.36 mg g-1), gallic acid (11.5 mg g-1), curcumin (2.75 mg g-1), catechin (3.9 mg g-1), and rosmarinic acid (5.54 mg g-1). Molecular docking studies with glucokinase showed that andrographolide yields the highest binding energy (-12.1 kcal mol-1), followed by catechin (-10.2 kcal mol-1), rosmarinic acid (-8.6 kcal mol-1), curcumin (-7.8 kcal mol-1), and gallic acid (-5.6 kcal mol-1). These current findings suggest that Synacinn™ at a dose of 250 mg kg-1 was non-toxic to rats. A twice-daily 250 mg kg-1 dose of Synacinn™ is an effective anti-hyperglycemic agent, lowering blood glucose, triglyceride, and cholesterol levels, and assisting the recovery of organ impairment caused by streptozotocin in type 1 diabetic rats.

Fructose Feeding and Hyperuricemia: a Systematic Review and Meta-Analysis

High fructose feeding has been suggested to involve in several features of metabolic syndrome including hyperuricemia (HP). We designed and implemented a study to determine the effect size of fructose intake and the relative risk of HP based on the type of fructose feeding (diet or solution), duration of treatment (2–6, 7–10, and > 10 weeks), and animal race. The required information was accepted from international databases, including PubMed/MEDLINE, Science Direct, Scopus, and etc., from 2009 until 2019 on the basis of predetermined eligibility criteria. The data selection and extraction and quality assessment were performed independently by two researchers. Results were pooled as random effects weighting and reported as standardized mean differences with 95% confidence intervals. Thirty-five studies including 244 rats with fructose consumption were included in the final analysis. The heterogeneity rate of parameters was high (I2 = 81.3%, p < 0.001) and estimated based on; 1) type of fructose feeding (diet; I2 = 79.3%, solution 10%; I2 = 83.4%, solution 20%; I2 = 81.3%), 2) duration of treatment (2–6 weeks; I2 = 86.8%, 7–10 weeks; I2 = 76.3%, and > 10 weeks; I2 = 82.8%), 3) the animal race (Wistar; I2 = 78.6%, Sprague-Dawley; I2 = 83.9%). Overall, the pooled estimate for the all parameters was significant (p < 0.001). The results of this study indicated that a significant relationship between HP and fructose intake regardless of the treatment duration, animal race, fructose concentration and route of consumption.

Potential of Curcumin in Skin Disorders

Curcumin is a compound isolated from turmeric, a plant known for its medicinal use. Recently, there is a growing interest in the medical community in identifying novel, low-cost, safe molecules that may be used in the treatment of inflammatory and neoplastic diseases. An increasing amount of evidence suggests that curcumin may represent an effective agent in the treatment of several skin conditions. We examined the most relevant in vitro and in vivo studies published to date regarding the use of curcumin in inflammatory, neoplastic, and infectious skin diseases, providing information on its bioavailability and safety profile. Moreover, we performed a computational analysis about curcumin's interaction towards the major enzymatic targets identified in the literature. Our results suggest that curcumin may represent a low-cost, well-tolerated, effective agent in the treatment of skin diseases. However, bypass of limitations of its in vivo use (low oral bioavailability, metabolism) is essential in order to conduct larger clinical trials that could confirm these observations. The possible use of curcumin in combination with traditional drugs and the formulations of novel delivery systems represent a very promising field for future applicative research.

Curcumin inhibits cigarette smoke-induced inflammation via modulating the PPARγ-NF-κB signaling pathway

The PPARγ-NF-κB signaling pathway is involved in the anti-inflammatory effect of curcumin on cigarette smoke-induced COPD models.

A Novel Solubility-Enhanced Rubusoside-Based Micelles for Increased Cancer Therapy

Many anti-cancer drugs have a common problem of poor solubility. Increasing the solubility of the drugs is very important for its clinical applications. In the present study, we revealed that the solubility of insoluble drugs was significantly enhanced by adding rubusoside (RUB). Further, it was demonstrated that RUB could form micelles, which was well characterized by Langmuir monolayer investigation, transmission electron microscopy, atomic-force microscopy, and cryogenic transmission electron microscopy. The RUB micelles were ellipsoid with the horizontal distance of ~25 nm and vertical distance of ~1.2 nm. Insoluble synergistic anti-cancer drugs including curcumin and resveratrol were loaded in RUB to form anti-cancer micelles RUB/CUR + RES. MTT assay showed that RUB/CUR + RES micelles had more significant toxicity on MCF-7 cells compared to RUB/CUR micelles + RUB/RES micelles. More importantly, it was confirmed that RUB could load other two insoluble drugs together for remarkably enhanced anti-cancer effect compared to that of RUB/one drug + RUB/another drug. Overall, we concluded that RUB-based micelles could efficiently load insoluble drugs for enhanced anti-cancer effect.

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

Background

Dyslipidemia is an important and common cardiovascular risk factor in the general population. The lipid-lowering effects of turmeric and curcumin are unconfirmed. We performed a meta-analysis to assess the efficacy and safety of turmeric and curcumin in lowering blood lipids in patients at risk of cardiovascular disease (CVD).

Methods

A comprehensive literature search was conducted on PubMed, Embase, Ovid, Medline and Cochrane Library databases to identify randomized controlled trials (published as of November 2016) that assessed the effect of turmeric and curcumin on blood lipid levels including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the effect.

Results

The analysis included 7 eligible studies (649 patients). Turmeric and curcumin significantly reduced serum LDL-C (SMD = −0.340, 95% confidence interval [CI]: −0.530 to −0.150, P < 0.0001) and TG (SMD = −0.214, 95% CI: −0.369 to −0.059, P = 0.007) levels as compared to those in the control group. These may be effective in lowering serum TC levels in patients with metabolic syndrome (MetS, SMD = −0.934, 95% CI: −1.289 to −0.579, P < 0.0001), and turmeric extract could possibly have a greater effect on reducing serum TC levels (SMD = −0.584, 95% CI: −0.980 to −0.188, P = 0.004); however, the efficacy is yet to be confirmed. Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies.

Conclusions

Turmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels. Curcumin may be used as a well-tolerated dietary adjunct to conventional drugs. Further research is required to resolve uncertainties related to dosage form, dose and medication frequency of curcumin.

Electronic supplementary material

The online version of this article (10.1186/s12937-017-0293-y) contains supplementary material, which is available to authorized users.